#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Antiphospholipid syndrome Paroxysmal nocturnal haemoglobinuria Deafness HER2 mutant non-small cell lung cancer Chronic graft versus host disease in intestine Congenital pseudarthrosis Antithrombin III deficiency Post transplant lymphoproliferative disorder Obesity Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency Multiple system atrophy Alpha-1 antitrypsin deficiency Superficial vein thrombosis Metastases to peritoneum Anaplastic thyroid cancer More trials…

    Learn about Rare Diseases

    Uterine leiomyosarcoma Myelodysplastic syndrome – Treatment Hairy cell leukaemia recurrent – Diagnostics Turner’s syndrome – Basic Information Noonan syndrome – Treatment MELAS syndrome – Diagnostics Isodicentric chromosome 15 syndrome – Diagnostics Lymphangioma – Treatment Rhabdomyosarcoma – Treatment Small intestine leiomyosarcoma – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Isis 678354 Sodium Salt INF904 Bisacodyl Abbv-668 Vgl101 Bi 764532 Vusolimogene Oderparepvec Magnesium Oxide, Light GSK5733584 Mva-Hbvac Abiraterone Acetate Chlorhexidine Dihydrochloride Sodium Chloride Pacritinib Dersimelagon Phosphate Amitriptyline Hydrochloride Liquid Paraffin Oxybutynin Busulfan Efmoroctocog Alfa More therapies…

    Learn about Your Condition

    Acne Affective disorder Juvenile absence epilepsy Medulloblastoma recurrent Peripheral artery stenosis Glioblastoma Stress cardiomyopathy Myopia Arteriovenous graft thrombosis Tuberous sclerosis complex Eye inflammation K-ras gene mutation Malformation venous Mental disorder Ischaemic stroke More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Systemic lupus erythematosus

  • Study of Obexelimab Treatment for Adults with Systemic Lupus Erythematosus (SLE)

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Obexelimab
    • Betamethasone Sodium Phosphate
    Belgium Bulgaria Denmark Germany Greece Italy +4

  • Study on MK-6194 for Adults with Systemic Lupus Erythematosus

    Not recruiting

    4 1
    Investigated Drugs:
    • Mk-6194
    France Italy Poland Spain

  • Study of Belimumab for Children with Systemic Lupus Erythematosus (SLE)

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Systemic lupus erythematosus
    Investigated Drugs:
    • Belimumab
    Germany Spain

  • Study on the Effectiveness and Safety of Obinutuzumab for Patients with Systemic Lupus Erythematosus

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Obinutuzumab
    Czechia France Italy Poland Spain

  • Study of Anifrolumab for Adults with Moderate-to-Severe Systemic Lupus Erythematosus

    Not recruiting

    4 1 1
    Investigated Diseases:
    • Systemic lupus erythematosus
    Investigated Drugs:
    • Anifrolumab
    Bulgaria Germany Hungary Poland Spain

  • Study on the Safety and Effects of YTB323, Fludarabine Phosphate, and Tocilizumab in Patients with Severe, Refractory Systemic Lupus Erythematosus

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Fludarabine Phosphate
    • Rapcabtagene Autoleucel
    • Cyclophosphamide
    France Germany Spain
Previous Page
1 … 5 6 7 8 9 10
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!